Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual ...

T wo clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers—follicular lymphoma and marginal zone ...

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...

This cell line originates from a patient’s Burkitt’s lymphoma and is often used in cancer research. The researchers brought the cells into contact with one of the four therapeutic antibodies ...

Like CAR-T cell therapy, in which immune cells ... a monoclonal antibody that helps further target the CAR-NK cells to lymphoma cells. A total of 10 study participants experienced low-grade ...

Prior to initiating therapy, if there is suspicion for transformation to a large-cell lymphoma (based on rapidly progressive adenopathy, elevated lactate dehydrogenase and/or development of B ...

BV, brentuximab vedotin; CAR-T, chimeric antigen receptor T-cell therapy; DLBCL, diffuse large B-cell lymphoma; Len, lenalidomide ... particularly as we await improved access to more effective options ...